Monitor daily volume and price action for actual ATM sales, any execution will accelerate dilution and likely pressure the stock.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 8 $1.85entry
- T+1 · 2mo ago +12.43%α +12.90% · $2.08
- T+5 · 2mo ago +96.76%α +97.88% · $3.64
- T+20 · 6w ago +40.00%α +38.29% · $2.59
- T+49 · todayOpen
- T+60 · in 15d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Indaptus Therapeutics filed Amendment No. 1 to its August 31, 2026 prospectus supplement, correcting a clerical error in the dilution calculation for its up-to-$100M at-the-market (ATM) offering through H.C. Wainwright. No shares have been sold under the ATM to date. The company has no active clinical programs, discontinued its lead candidate Decoy20, and faces a going-concern risk. The ATM creates massive potential dilution (up to 87.7M shares at $1.14/share, representing ~66% of current outstanding shares), compounding the existing overhang from two prior S-3 resale registrations.
Key Facts
- ATM offering of up to $100M in common stock via H.C. Wainwright; no shares sold as of Sept 4, 2026
- Stock price $1.17 as of Sept 2, 2026; assumed offering price $1.14 per share
- Net tangible book value $0.09/share as of June 30, 2026; pro forma dilution of $0.65/share to new investors
- Company has no active clinical programs and auditor expressed substantial doubt about going concern
- Two prior S-3 filings (Aug 17 and June 26, 2026) registered ~58.9M and ~18.9M shares for resale by selling stockholders
Financial Impact
Up to $100M gross proceeds from ATM; pro forma dilution of $0.65/share (57% dilution from current $0.09 book value per share at assumed $1.14 price)
Risk Factors
- Massive dilution from ATM sales and existing resale registrations
- No active clinical programs or revenue; going-concern risk
- Potential for further equity raises or reverse splits
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-041526 |
| Document: 0001493152-26-041526-index-headers.html | 0001493152-26-041526 |
| Document: 0001493152-26-041526-index.html | 0001493152-26-041526 |
| Document: 0001493152-26-041526.txt | 0001493152-26-041526 |
Track record
20 reports on INDP
4 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +59.35% at T+20 after the Jul 20, 2026 report. 6 of 9 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.17 Now $3.45 +8.83% settles Dec 15
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
- Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
- Sep 9, 20269w ago 8-K Bearish 7/10 Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
- Sep 4, 202610w ago 424B5 Bearish 6/10 Viewing Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
- Sep 1, 202610w ago 8-K Bearish 5/10 Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers